129 related articles for article (PubMed ID: 7529527)
1. Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours.
Kornek G; Schenk T; Raderer M; Djavarnmad M; Scheithauer W
Br J Cancer; 1995 Jan; 71(1):182-5. PubMed ID: 7529527
[TBL] [Abstract][Full Text] [Related]
2. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.
Ward U; Primrose JN; Finan PJ; Perren TJ; Selby P; Purves DA; Cooper EH
Br J Cancer; 1993 May; 67(5):1132-5. PubMed ID: 8494712
[TBL] [Abstract][Full Text] [Related]
3. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements.
Glimelius B; Hoffman K; Einarsson R; Pählman L; Graf W
Acta Oncol; 1996; 35(2):141-8. PubMed ID: 8639308
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
5. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9.
Slesak B; Harlozinska-Szmyrka A; Knast W; Sedlaczek P; van Dalen A; Einarsson R
Cancer; 2000 Jul; 89(1):83-8. PubMed ID: 10897004
[TBL] [Abstract][Full Text] [Related]
6. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
7. Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma.
Berglund A; Molin D; Larsson A; Einarsson R; Glimelius B
Ann Oncol; 2002 Sep; 13(9):1430-7. PubMed ID: 12196369
[TBL] [Abstract][Full Text] [Related]
8. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
Carpelan-Holmström M; Haglund C; Lundin J; Alfthan H; Stenman UH; Roberts PJ
Br J Cancer; 1996 Sep; 74(6):925-9. PubMed ID: 8826859
[TBL] [Abstract][Full Text] [Related]
9. The value of TPS in breast cancer.
Karaloglu D; Yasasever V; Ertürk N; Dalay N
Eur J Gynaecol Oncol; 1995; 16(5):363-7. PubMed ID: 8549601
[TBL] [Abstract][Full Text] [Related]
10. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L
Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030
[TBL] [Abstract][Full Text] [Related]
11. [Advances regarding tumor markers in bladder cancer].
Moreno Sierra J; Chicharro Almarza GJ; Torronteras Santiago JM; Ortega Heredia MD; Maestro de las Casas ML; Silmi Moyano A; Resel Estévez L
Actas Urol Esp; 1997 Mar; 21(3):195-205. PubMed ID: 9324884
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Tumour Biol; 1994; 15(1):52-60. PubMed ID: 8146530
[TBL] [Abstract][Full Text] [Related]
13. Serological markers for metastatic breast cancer.
Ng JS; Sturgeon CM; Seth J; Paterson GM; Roulston JE; Leonard RC
Dis Markers; 1993 Dec; 11(5-6):217-23. PubMed ID: 8082311
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Plebani M; Basso D; Del Favero G; Ferrara C; Meggiato T; Fogar P; Mangano F; Ricciardi G; Burlina A
Oncology; 1993; 50(6):436-40. PubMed ID: 8233283
[TBL] [Abstract][Full Text] [Related]
15. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
16. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients.
Cohen AD; Gopas J; Karplus G; Cohen Y
Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
18. New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer.
Locker GJ; Mader RM; Braun J; Sieder AE; Marosi C; Rainer H; Jakesz R; Steger GG
Oncology; 1995; 52(2):140-4. PubMed ID: 7854774
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers in pleural effusions.
Topolcan O; Holubec L; Polivkova V; Svobodova S; Pesek M; Treska V; Safranek J; Hajek T; Bartunek L; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1921-4. PubMed ID: 17649796
[TBL] [Abstract][Full Text] [Related]
20. Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer.
Sjöström J; Alfthan H; Joensuu H; Stenman UH; Lundin J; Blomqvist C
Scand J Clin Lab Invest; 2001; 61(6):431-41. PubMed ID: 11681532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
